AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2844641 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy-tryptophan (5OHT) after dexamethasone pretreatment
Number of subjects: 8
Study 2844641 — intervention group
Group type: COMPARATOR
Intervention: pizotifen (Piz)
Number of subjects: 8
Study 2844641 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 31743131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk HPV (lrHPV) RNA positive IPs
Number of subjects: 44
Study 31743131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk HPV (lrHPV) RNA negative IPs
Number of subjects: 44
Study 31743131 — intervention group
Group type: COMPARATOR
Intervention: Control nonkeratinizing SCCs
Number of subjects: 44
Study 29438110 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training module followed by a test module
Number of subjects: 463
Study 29438110 — intervention group
Group type: COMPARATOR
Intervention: Test module followed by training module (Control)
Number of subjects: 463
Study 29438110 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement for intervention
Number of subjects: 463
Study 29438110 — intervention group
Group type: COMPARATOR
Intervention: Overall agreement for control
Number of subjects: 463
Study 28192622 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg/day
Number of subjects: 180
Study 28192622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 26193861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus root
Number of subjects: 0
Study 26193861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cucumber
Number of subjects: 0
Study 26193861 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 23728065 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/d, titrated during the first week)
Number of subjects: 200
Study 23728065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 22215943 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) with Peg‐α‐2b interferon (1.5 μg/kg per week) plus ribavirin (1000‐1200 mg/d)
Number of subjects: 72
Study 22215943 — intervention group
Group type: COMPARATOR
Intervention: Peg‐α‐2b interferon (1.5 μg/kg per week) plus ribavirin (1000‐1200 mg/d) without vitamin D
Number of subjects: 72
Study 18987881 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed tool use with constant joint and switching target-to-movement mapping
Number of subjects: 0
Study 18987881 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed tool use with constant target-to-movement mapping
Number of subjects: 0
Study 16813138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental floss
Number of subjects: 50
Study 16813138 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical interdental brush
Number of subjects: 50
Study 16813138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylindrical interdental brush
Number of subjects: 50
Study 12627316 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes screening
Number of subjects: 1353
Study 12627316 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) screening
Number of subjects: 1353
Study 12627316 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG) screening
Number of subjects: 1353
Study 12627316 — intervention group
Group type: EXPERIMENTAL
Intervention: NNTS for undiagnosed diabetes in men
Number of subjects: 1353
Study 12627316 — intervention group
Group type: EXPERIMENTAL
Intervention: NNTS for undiagnosed diabetes in women
Number of subjects: 1353
Study 11114637 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 53
Study 11114637 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 53
Study 9021432 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (LMWH)
Number of subjects: 0
Study 9021432 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin
Number of subjects: 0
Study 8471571 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (benzodiazepine antagonist)
Number of subjects: 40
Study 8471571 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 40
Study 3437446 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and nicotine chewing gum
Number of subjects: 0
Study 3437446 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29420721 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cryoballoon application per vein
Number of subjects: 140
Study 29420721 — intervention group
Group type: COMPARATOR
Intervention: Routine dual cryoballoon application
Number of subjects: 140
Study 26923987 — intervention group
Group type: COMPARATOR
Intervention: GDF5
Number of subjects: 0
Study 26923987 — intervention group
Group type: COMPARATOR
Intervention: PTH (1‐34) Teriparatide
Number of subjects: 0
Study 25529979 — intervention group
Group type: EXPERIMENTAL
Intervention: LX4211 (400 mg for 7 days)
Number of subjects: 31
Study 25529979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23765420 — intervention group
Group type: EXPERIMENTAL
Intervention: C-seal
Number of subjects: 37
Study 20514695 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT with hyperventilation
Number of subjects: 25
Study 20514695 — intervention group
Group type: COMPARATOR
Intervention: ECT without hyperventilation
Number of subjects: 25
Study 20514695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 18401199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily injections with indwelling catheter (Group A)
Number of subjects: 40
Study 18401199 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections without indwelling catheter (Group B)
Number of subjects: 40
Study 20638772 — intervention group
Group type: EXPERIMENTAL
Intervention: Straddling external chest compression
Number of subjects: 20
Study 20638772 — intervention group
Group type: COMPARATOR
Intervention: Standard external chest compression
Number of subjects: 20
Study 15791507 — intervention group
Group type: EXPERIMENTAL
Intervention: Maki's semiquantitative technique
Number of subjects: 1000
Study 15791507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonication
Number of subjects: 1000
Study 15791507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortexing
Number of subjects: 1000
Study 11495387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-led ward care (treatment group)
Number of subjects: 177
Study 11495387 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 177
Study 9773742 — intervention group
Group type: EXPERIMENTAL
Intervention: Good-to-moderate glycemic control (GHb <= 9%)
Number of subjects: 97
Study 9773742 — intervention group
Group type: COMPARATOR
Intervention: Poor glycemic control (GHb >= 9%)
Number of subjects: 97
Study 9773742 — intervention group
Group type: EXPERIMENTAL
Intervention: GHb as a continuous variable
Number of subjects: 97
Study 9773742 — intervention group
Group type: EXPERIMENTAL
Intervention: GHb as a categorical variable with cutoff level of 9%
Number of subjects: 97
Study 9773742 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes
Number of subjects: 97
Study 9773742 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes, age, and male sex
Number of subjects: 97
Study 7820976 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine infusion (1 g h‐1)
Number of subjects: 11
Study 7820976 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (20 g h‐1)
Number of subjects: 11
Study 7820976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of leucine and glucose infusions
Number of subjects: 11
Study 2970367 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 18
Study 2970367 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate (NET-EN)
Number of subjects: 18
Study 30536154 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH glasdegib (100 mg)
Number of subjects: 24
Study 30536154 — intervention group
Group type: COMPARATOR
Intervention: ICH glasdegib (100 mg) after high-fat, high-calorie meal
Number of subjects: 24
Study 30536154 — intervention group
Group type: COMPARATOR
Intervention: ICH glasdegib (100 mg) with PPI (rabeprazole)
Number of subjects: 24
Study 28994677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine (DK)
Number of subjects: 60
Study 28994677 — intervention group
Group type: COMPARATOR
Intervention: Propofol-ketamine (PK)
Number of subjects: 60
Study 26615369 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin challenge
Number of subjects: 38
Study 26615369 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 38
Study 26615369 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels in AERD patients
Number of subjects: 38
Study 25295770 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity prescription intervention targeting exercise intensity
Number of subjects: 60
Study 25295770 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity prescription intervention targeting sedentary intensity
Number of subjects: 60
Study 25295770 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity prescription intervention targeting both exercise and sedentary intensity
Number of subjects: 60
Study 25295770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 60
Study 23181957 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counselling
Number of subjects: 116
Study 23181957 — intervention group
Group type: COMPARATOR
Intervention: Written information
Number of subjects: 116
Study 19390069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI)
Number of subjects: 35
Study 19390069 — intervention group
Group type: COMPARATOR
Intervention: Conventional Functional Rehabilitation (FR)
Number of subjects: 35
Study 17722433 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue scraper used 2-3 times a day
Number of subjects: 10
Study 17722433 — intervention group
Group type: COMPARATOR
Intervention: No tongue scraper (control)
Number of subjects: 10
Study 15500257 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfrey extract ointment (Kytta-Salbe f, four treatments per day for 8 days)
Number of subjects: 142
Study 15500257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 11584376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 25 mg daily
Number of subjects: 159
Study 11584376 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg 3 times a day before lamivudine 100 mg daily
Number of subjects: 159
Study 11584376 — intervention group
Group type: EXPERIMENTAL
Intervention: YMDD variants present 3 months before HBV DNA breakthroughs
Number of subjects: 159
Study 11584376 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HBV DNA breakthroughs
Number of subjects: 159
Study 11584376 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA levels > 10(3) copies/mL after 6 months of lamivudine therapy
Number of subjects: 159
Study 11584376 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg seroconversion
Number of subjects: 159
Study 9693949 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular questioning style
Number of subjects: 120
Study 9693949 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexive questioning style
Number of subjects: 120
Study 9693949 — intervention group
Group type: COMPARATOR
Intervention: Lineal questioning style
Number of subjects: 120
Study 9693949 — intervention group
Group type: COMPARATOR
Intervention: Strategic questioning style
Number of subjects: 120
Study 7872992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine treatment for one week
Number of subjects: 22
Study 7872992 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for one week
Number of subjects: 22
Study 3279350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 20
Study 3279350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29426379 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable DCD
Number of subjects: 0
Study 27272937 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention (n=60): instructed to walk briskly for 30 minutes, three times weekly from 30 weeks' gestation until delivery
Number of subjects: 118
Study 27272937 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=58): counted daily steps using pedometers
Number of subjects: 118
Study 24112810 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacement (MR) group
Number of subjects: 46
Study 24112810 — intervention group
Group type: COMPARATOR
Intervention: Conventional reduced-fat diet (CD) group
Number of subjects: 46
Study 22571244 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 80
Study 22571244 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study 19844211 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 9
Study 19844211 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 9
Study 18029109 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 55
Study 18029109 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (for subjects who received the study drug for more than 2 months)
Number of subjects: 55
Study 18029109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for subjects who received the study drug for more than 2 months)
Number of subjects: 55
Study 15738010 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of gentamicin (5.1 mg/kg every 24 hours; n = 18)
Number of subjects: 38
Study 15738010 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of gentamicin (120 mg followed by 80 mg every 8 hours; n = 20)
Number of subjects: 38
Study 15738010 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of gentamicin
Number of subjects: 38
Study 15738010 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of gentamicin
Number of subjects: 38
Study 12166534 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/day of vitamin D3
Number of subjects: 50
Study 12166534 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 50
Study 10592457 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH, 15.5 IU/m(2) body surface per week, subcutaneously, for at least 2 years
Number of subjects: 552
Study 10592457 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy in three dosage groups for girls with Turner's syndrome: Group A (4 IU/m(2)), Group B (4 IU/m(2) first year, 6 IU/m(2) thereafter), Group C (4 IU/m(2) first year, 6 IU/m(2) second year, 8 IU/m(2) thereafter)
Number of subjects: 552
Study 8521713 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and misoprostol
Number of subjects: 86
Study 2253495 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 30
Study 2253495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 30
Study 2253495 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 30
Study 2253495 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics (netilmicin and tobramycin)
Number of subjects: 30
Study 337746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 40
Study 337746 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study 30451604 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial empowerment program based on the Integrative Body-Mind-Spirit model; delivered in a parallel group format.
Number of subjects: 0
Study 30451604 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group; no intervention provided during the study period.
Number of subjects: 0
Study 27215298 — intervention group
Group type: EXPERIMENTAL
Intervention: Free sachet water vouchers (15 L/week/child) plus education
Number of subjects: 86
Study 27215298 — intervention group
Group type: COMPARATOR
Intervention: Half-price sachet water vouchers (15 L/week/child) plus education
Number of subjects: 86
Study 27215298 — intervention group
Group type: COMPARATOR
Intervention: Control group received education about diarrhea
Number of subjects: 86
Study 24006222 — intervention group
Group type: EXPERIMENTAL
Intervention: More than two immunotherapies
Number of subjects: 60
Study 24006222 — intervention group
Group type: COMPARATOR
Intervention: Two immunotherapies
Number of subjects: 60
Study 21752101 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus Mycophenolate mofetil (3 g/day, 1.5 g twice daily)
Number of subjects: 47
Study 21752101 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone (1 mg/kg)
Number of subjects: 47
Study 19925203 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening group
Number of subjects: 60
Study 19925203 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio book listening group
Number of subjects: 60
Study 19925203 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 18207164 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV‐VRT
Number of subjects: 10
Study 18207164 — intervention group
Group type: COMPARATOR
Intervention: seeing field‐VRT
Number of subjects: 10
Study 15753541 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg daily
Number of subjects: 50
Study 15753541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12519419 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) treatment (0.04 U/kg/day for 14 weeks preoperatively and doubled for the first 2 weeks postoperatively)
Number of subjects: 33
Study 12519419 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) treatment
Number of subjects: 33
Study 12519419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10770449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 64
Study 10770449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 9075195 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing palm-olein, high oleic sunflower, coconut and soy oil
Number of subjects: 172
Study 9075195 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing coconut and soy oil
Number of subjects: 172
Study 9075195 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed
Number of subjects: 172
Study 9075195 — intervention group
Group type: EXPERIMENTAL
Intervention: All infant groups
Number of subjects: 172
Study 8441966 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine intraoperative cholangiography (IOC)
Number of subjects: 280
Study 8441966 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative cholangiography (no-IOC)
Number of subjects: 280
Study 3097099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 28
Study 3097099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29843467 — intervention group
Group type: EXPERIMENTAL
Intervention: New HM fortifier (nHMF; n = 26) containing 12.5 g medium‐chain FA, 958 mg linoleic acid, 417 mg α‐linolenic acid, and 157 mg docosahexaenoic acid per 100 g of powder
Number of subjects: 47
Study 29843467 — intervention group
Group type: COMPARATOR
Intervention: Fat-free HMF (cHMF; n = 21)
Number of subjects: 47
Study 26889350 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mm locking plates
Number of subjects: 20
Study 26889350 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mm nonlocking (traditional) plates
Number of subjects: 20
Study 23821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Any vertebral fracture
Number of subjects: 576
Study 23821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild vertebral fractures discounted
Number of subjects: 576
Study 23821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild vertebral fractures
Number of subjects: 576
Study 23821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate vertebral fractures
Number of subjects: 576
Study 23821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe vertebral fractures
Number of subjects: 576
Study 23821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative fracture grades 1 to 3
Number of subjects: 576
Study 23821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative fracture grades 4 to 6
Number of subjects: 576
Study 23821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative fracture grades ≥7
Number of subjects: 576
Study 22872363 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Focus Curved Shears
Number of subjects: 19
Study 22872363 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 19
Study 20307126 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief image‐based prevention intervention
Number of subjects: 416
Study 20307126 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 416
Study 18604681 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin mesh
Number of subjects: 86
Study 18604681 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone or polyglactin sutures
Number of subjects: 86
Study 18604681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no polyglactin mesh)
Number of subjects: 86
Study 16001680 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation-specific polymerase chain reaction (MSP) assay for p16
Number of subjects: 63
Study 16001680 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation-specific polymerase chain reaction (MSP) assay for E‐cadherin
Number of subjects: 63
Study 16001680 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation-specific polymerase chain reaction (MSP) assay for RARbeta
Number of subjects: 63
Study 16001680 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation-specific polymerase chain reaction (MSP) assay overall
Number of subjects: 63